← Back to Search

Fatty Acid

Omega-3 fatty acids for Pulmonary Hypertension

N/A
Waitlist Available
Research Sponsored by Wen-Chih Wu
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult men and women > 30 years of age with a diagnosis of pulmonary hypertension (defined as mean pulmonary arterial pressure ≥25 mmHg at rest on right heart catheterization)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

The goal of this study is to elucidate the relationship between myocardial right ventricular triglyceride content (steatosis) and right ventricular dysfunction in participants with pulmonary hypertension, and investigate reversibility of this phenotype with omega-3 fatty acid treatment.

Eligible Conditions
  • Pulmonary Hypertension
  • Fatty Liver
  • Right Ventricular Failure

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Right ventricular myocardial triglyceride content (by cardiac MRI) in 30 participants with pulmonary hypertension
Secondary outcome measures
Right ventricular ejection fraction (by cardiac MRI) in 30 participants with pulmonary hypertension

Side effects data

From 2017 Phase 4 trial • 413 Patients • NCT02642159
5%
Diarrhoea
5%
Urinary tract infection
2%
Arthralgia
2%
Bronchitis
1%
Angina unstable
1%
Ischaemic stroke
1%
Non-cardiac chest pain
1%
Pneumonia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Alirocumab 75 mg Q2W/Up to 150 mg Q2W
Usual Care

Trial Design

1Treatment groups
Experimental Treatment
Group I: Omega-3 fatty acidsExperimental Treatment1 Intervention
30 patients with pulmonary hypertension who are identified as having elevated myocardial triglyceride content by cardiac MRI will receive 4 grams/day of omega-3 fatty acids for six months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Omega-3 fatty acids
2018
Completed Phase 4
~2640

Find a Location

Who is running the clinical trial?

Wen-Chih WuLead Sponsor
Providence VA Medical CenterLead Sponsor
26 Previous Clinical Trials
72,453 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Reversal of Right Ventricular Steatosis in Pulmonary Hypertension
Wen-Chih Wu 2016. "Reversal of Right Ventricular Steatosis in Pulmonary Hypertension". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02966899.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top